ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CARA Cara Therapeutics Inc

0.7782
0.006 (0.78%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cara Therapeutics Inc NASDAQ:CARA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.006 0.78% 0.7782 0.7715 0.7815 0.7969 0.7571 0.7969 159,125 22:05:25

Cara Therapeutics to Webcast Presentation at the 16th Annual Needham Healthcare Conference

28/03/2017 9:30pm

GlobeNewswire Inc.


Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cara Therapeutics Charts.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017, at 9:20 a.m. ET in New York City.

A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200 
michael@sternir.com

MEDIA CONTACT: 
Annie Starr
6 Degrees
973-415-8838 
astarr@6degreespr.com 

1 Year Cara Therapeutics Chart

1 Year Cara Therapeutics Chart

1 Month Cara Therapeutics Chart

1 Month Cara Therapeutics Chart

Your Recent History

Delayed Upgrade Clock